Literature DB >> 14665390

A historical view of schistosomiasis japonica in the Chikugo river basin. What can we learn from autopsy?

Toshiro Nakashima1, Masayoshi Kage, Mizuki Hirata.   

Abstract

Three hundred and forty-nine autopsy cases of schistosomiasis japonica were divided into two groups, based on the pathomorphology. Frequent regressive hepatic lesions such as active schistosomal lesion and destruction of limiting plates characterized the first group. The second group showed reparative hepatic lesions such as regeneration of the collapsed parenchyma, newly formed limiting plates and subsequent narrowing and disappearance of fibrous septa. Complications of liver cirrhosis and hepatocellular carcinoma related to viral hepatitis B and/or C also increased. Clonorchiasis was consistently found in both groups.

Entities:  

Mesh:

Year:  2003        PMID: 14665390     DOI: 10.1016/j.parint.2003.09.004

Source DB:  PubMed          Journal:  Parasitol Int        ISSN: 1383-5769            Impact factor:   2.230


  3 in total

1.  Intrahepatic cholangiocarcinoma with old infestation of Schistosoma japonicum: report of a case.

Authors:  Tomotaka Akatsu; Motohide Shimazu; Masahiro Shinoda; Shigeyuki Kawachi; Minoru Tanabe; Koichi Aiura; Masakazu Ueda; Kaori Kameyama; Michiie Sakamoto; Masaki Kitajima; Yuko Kitagawa
Journal:  Surg Today       Date:  2007-09-26       Impact factor: 2.549

2.  Chronic schistosomiasis japonica is an independent adverse prognostic factor for survival in hepatocellular carcinoma patients who have undergone hepatic resection: clinicopathological and prognostic analysis of 198 consecutive patients.

Authors:  Masanori Matsuda; Hideki Fujii
Journal:  World J Surg       Date:  2009-12       Impact factor: 3.352

Review 3.  Disseminated peritoneal Schistosoma japonicum: a case report and review of the pathological manifestations of the helminth.

Authors:  Salah Al-Waheeb; Maryam Al-Murshed; Fareeda Dashti; Parsotam R Hira; Lamia Al-Sarraf
Journal:  Ann Saudi Med       Date:  2009 Mar-Apr       Impact factor: 1.526

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.